Physician profile
Michael L Hoffman
NPI 1831190008
$10,461.63
in general payments reported to CMS, 2019-2025
26 companies · $851 in 2025
The $851 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,323 · 2020: $803 · 2021: $954 · 2022: $1,577 · 2023: $1,764 · 2024: $1,190 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,644 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,644.44 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,533.92 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,560.62 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $819.39 | 2019-2023 | Tremfya, Stelara, Remicade |
| Amgen INC. | $793.56 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Mallinckrodt Enterprises LLC | $551.09 | 2019 | |
| Pfizer INC. | $447.41 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $304.71 | 2021-2025 | Saphnelo |
| Hikma Pharmaceuticals USA | $263.56 | 2019-2022 | |
| Horizon Therapeutics Plc | $207.71 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $199.95 | 2021-2023 | Tremfya |
| Ani Pharmaceuticals, INC. | $140.16 | 2022-2023 | Purified Cortrophin Gel |
| Celgene Corporation | $136.96 | 2019 | |
| Medexus Pharma, INC. | $118.86 | 2019 | |
| Lilly USA, LLC | $81.47 | 2020-2022 | |
| Ucb, INC. | $52.60 | 2023-2025 | Bimzelx, Cimzia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.28 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $28.10 | 2025 | Orencia |
| Genentech USA, INC. | $24.53 | 2020 | |
| Glaxosmithkline, LLC. | $24.35 | 2020 | |
| Alexion Pharmaceuticals, INC. | $23.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.20 | 2019 | |
| Merck Sharp & Dohme LLC | $20.00 | 2019 | |
| Tactile Systems Technology INC | $19.14 | 2022 | |
| Intuitive Surgical, INC. | $19.00 | 2022 | |
| Seqirus USA INC | $15.09 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.